Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network

BACKGROUND: This study aims at describing the therapeutic outcome of patients carrying the R92Q variant in the TNFRSF1A gene treated with anakinra (ANA) or canakinumab (CAN) and identifying any factors predictive of complete response to IL-1 inhibition. METHODS: Clinical data of patients treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaggiano, Carla, Rigante, Donato, Hernández-Rodríguez, José, Vitale, Antonio, Tarsia, Maria, Soriano, Alessandra, Lopalco, Giuseppe, Iannone, Florenzo, Abdel Jaber, Masen, Giacomelli, Roberto, Wiȩsik-Szewczyk, Ewa, Cattalini, Marco, Frassi, Micol, Piga, Matteo, Ragab, Gaafar, Sota, Jurgen, Zunica, Fiammetta, Floris, Alberto, Sabato, Vito, Hegazy, Mohamed Tharwat, Araújo, Olga, Pelegrín, Laura, Fabbiani, Alessandra, Renieri, Alessandra, Grosso, Salvatore, Fabiani, Claudia, Frediani, Bruno, Cantarini, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436281/
https://www.ncbi.nlm.nih.gov/pubmed/34527082
http://dx.doi.org/10.1177/1759720X211037178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436281/
https://www.ncbi.nlm.nih.gov/pubmed/34527082
http://dx.doi.org/10.1177/1759720X211037178

Ejemplares similares